Special Issue

Anti-inflammatory Property of Probiotics

Message from the Guest Editors

Probiotics are used to treat chronic diseases, especially diseases that involve immune system modulation. The role of probiotics is observed in improving the conditions in some gastrointestinal diseases such as inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC). The scope of this Special Issue will cover the role of different probiotics in anti-inflammatory effects in animal and human subjects. Special emphasis will be on mechanistic pathways of disease control and remission. In addition, we welcome the development or discovery of novel probiotic strains of a potential anti-inflammatory effect on animals and humans. The Special Issue welcomes original research articles, reviews, and clinical trials. We look forward to receiving your contributions.

Guest Editors

Dr. Bassam Abomoelak

Pediatric Specialty Laboratory, Arnold Palmer Hospital, Orlando Health, Orlando, FL 32806, USA

Prof. Dr. Hesham Ali El Enshasy

Institute of Bioproduct Development (IBD), Universiti Teknologi Malaysia (UTM), Skudai, Johor Bahru 81310, Malaysia

Deadline for manuscript submissions

closed (15 October 2024)



Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/133092

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms





Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

